A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression

Karen Wagner, Jeffrey Jonas, Robert L. Findling, Daniel Ventura, Khalil Saikali

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Objective: Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression. Method: Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133). Randomization was not stratified by age. The primary efficacy measure was the mean change from baseline to endpoint in Children's Depression Rating Scale-Revised (CDRS-R) scores, using the last observation carried forward approach. Results: A total of 82% of patients completed treatment. Escitalopram did not significantly improve CDRS-R scores compared to placebo at endpoint (least squares mean difference = -1.7, p = .31; last observation carried forward). In a post hoc analysis of adolescent (ages 12-17 years) completers, escitalopram significantly improved CDRS-R scores compared with placebo (least squares mean difference = -4.6, p = .047). Headache and abdominal pain were the only adverse events in >10% of patients in the escitalopram group. Discontinuation rates caused by adverse events were 1.5% for both groups. Potential suicide-related events were observed in one escitalopram-and two placebo-treated patients. There were no completed suicides. Conclusions: Although there were no significant differences between escitalopram and placebo in the total population, the data suggest that escitalopram may have beneficial effects in adolescent patients. Escitalopram appeared to be well tolerated.

Original languageEnglish (US)
Pages (from-to)280-288
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Citalopram
Randomized Controlled Trials
Placebos
Depression
Pediatrics
Therapeutics
Least-Squares Analysis
Suicide
Observation
Major Depressive Disorder
Serotonin Uptake Inhibitors
Random Allocation
Evoked Potentials
Abdominal Pain
Antidepressive Agents
Headache
Safety

Keywords

  • Escitalopram
  • Pediatric
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. / Wagner, Karen; Jonas, Jeffrey; Findling, Robert L.; Ventura, Daniel; Saikali, Khalil.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 3, 03.2006, p. 280-288.

Research output: Contribution to journalArticle

@article{7596f37304494f0eb554efcb3ab6724b,
title = "A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression",
abstract = "Objective: Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression. Method: Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133). Randomization was not stratified by age. The primary efficacy measure was the mean change from baseline to endpoint in Children's Depression Rating Scale-Revised (CDRS-R) scores, using the last observation carried forward approach. Results: A total of 82{\%} of patients completed treatment. Escitalopram did not significantly improve CDRS-R scores compared to placebo at endpoint (least squares mean difference = -1.7, p = .31; last observation carried forward). In a post hoc analysis of adolescent (ages 12-17 years) completers, escitalopram significantly improved CDRS-R scores compared with placebo (least squares mean difference = -4.6, p = .047). Headache and abdominal pain were the only adverse events in >10{\%} of patients in the escitalopram group. Discontinuation rates caused by adverse events were 1.5{\%} for both groups. Potential suicide-related events were observed in one escitalopram-and two placebo-treated patients. There were no completed suicides. Conclusions: Although there were no significant differences between escitalopram and placebo in the total population, the data suggest that escitalopram may have beneficial effects in adolescent patients. Escitalopram appeared to be well tolerated.",
keywords = "Escitalopram, Pediatric, Selective serotonin reuptake inhibitor",
author = "Karen Wagner and Jeffrey Jonas and Findling, {Robert L.} and Daniel Ventura and Khalil Saikali",
year = "2006",
month = "3",
doi = "10.1097/01.chi.0000192250.38400.9e",
language = "English (US)",
volume = "45",
pages = "280--288",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression

AU - Wagner, Karen

AU - Jonas, Jeffrey

AU - Findling, Robert L.

AU - Ventura, Daniel

AU - Saikali, Khalil

PY - 2006/3

Y1 - 2006/3

N2 - Objective: Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression. Method: Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133). Randomization was not stratified by age. The primary efficacy measure was the mean change from baseline to endpoint in Children's Depression Rating Scale-Revised (CDRS-R) scores, using the last observation carried forward approach. Results: A total of 82% of patients completed treatment. Escitalopram did not significantly improve CDRS-R scores compared to placebo at endpoint (least squares mean difference = -1.7, p = .31; last observation carried forward). In a post hoc analysis of adolescent (ages 12-17 years) completers, escitalopram significantly improved CDRS-R scores compared with placebo (least squares mean difference = -4.6, p = .047). Headache and abdominal pain were the only adverse events in >10% of patients in the escitalopram group. Discontinuation rates caused by adverse events were 1.5% for both groups. Potential suicide-related events were observed in one escitalopram-and two placebo-treated patients. There were no completed suicides. Conclusions: Although there were no significant differences between escitalopram and placebo in the total population, the data suggest that escitalopram may have beneficial effects in adolescent patients. Escitalopram appeared to be well tolerated.

AB - Objective: Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression. Method: Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133). Randomization was not stratified by age. The primary efficacy measure was the mean change from baseline to endpoint in Children's Depression Rating Scale-Revised (CDRS-R) scores, using the last observation carried forward approach. Results: A total of 82% of patients completed treatment. Escitalopram did not significantly improve CDRS-R scores compared to placebo at endpoint (least squares mean difference = -1.7, p = .31; last observation carried forward). In a post hoc analysis of adolescent (ages 12-17 years) completers, escitalopram significantly improved CDRS-R scores compared with placebo (least squares mean difference = -4.6, p = .047). Headache and abdominal pain were the only adverse events in >10% of patients in the escitalopram group. Discontinuation rates caused by adverse events were 1.5% for both groups. Potential suicide-related events were observed in one escitalopram-and two placebo-treated patients. There were no completed suicides. Conclusions: Although there were no significant differences between escitalopram and placebo in the total population, the data suggest that escitalopram may have beneficial effects in adolescent patients. Escitalopram appeared to be well tolerated.

KW - Escitalopram

KW - Pediatric

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33645107359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645107359&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000192250.38400.9e

DO - 10.1097/01.chi.0000192250.38400.9e

M3 - Article

VL - 45

SP - 280

EP - 288

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 3

ER -